Company About Board of Directors Leadership News & Media Careers

News & Media

Latest news

FEATURED ARTICLE

News & Media

Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy™ in the Most Challenging Arteries Below-the-Ankle

Read more →

The Serranator to be featured in the upcoming Limb Salvage Issue of Endovascular Today

Meg McConnell 5/26/20 Meg McConnell 5/26/20

The Serranator to be featured in the upcoming Limb Salvage Issue of Endovascular Today

Read More

The Serranator is featured in the Endovascular Today – Limb Salvage Issue

Meg McConnell 5/6/20 Meg McConnell 5/6/20

The Serranator is featured in the Endovascular Today – Limb Salvage Issue

Read More

Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment

Meg McConnell 4/23/20 Meg McConnell 4/23/20

Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment

Read More

Cagent Vascular Initiates Enrollment of PRELUDE-BTK Study Using Serranator Device

Meg McConnell 1/7/20 Meg McConnell 1/7/20

Cagent Vascular Initiates Enrollment of PRELUDE-BTK Study Using Serranator Device

Read More

Cagent Vascular Appoints Medical Device Industry Veteran Brian Walsh as Chairman of the Board

Meg McConnell 10/9/18 Meg McConnell 10/9/18

Cagent Vascular Appoints Medical Device Industry Veteran Brian Walsh as Chairman of the Board

Read More

Cagent Vascular announce CE Mark of SERRANATOR®, next generation device for vessel dilatation in peripheral artery disease interventions

Meg McConnell 11/20/17 Meg McConnell 11/20/17

Cagent Vascular announce CE Mark of SERRANATOR®, next generation device for vessel dilatation in peripheral artery disease interventions

Read More

Cagent Vascular Completes Enrollment of PRELUDE Study Using Serranator Device

Meg McConnell 6/5/17 Meg McConnell 6/5/17

Cagent Vascular Completes Enrollment of PRELUDE Study Using Serranator Device

Read More